Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Latha Vairavan – Vice President, Finance and Head of Investor RelationsFrank Watanabe – President and Chief Executive OfficerTodd Edwards – Chief Commercial OfficerPatrick Burnett – Chief Medical OfficerDavid Topper – Chief Financial Officer Conference Call Participants Serge Belanger…
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Conference Call February 27, 2024 8:30 AM ET Company Participants Derek Cole – IR Frank Watanabe – President and CEO Todd Edwards – CCO Patrick Burnett – CMO John Smither – CFO Conference Call Participants Tyler Van Buren – TD Cowen Uy Ear – Mizuho Chris Shibutani –…
sruilk/iStock via Getty Images Investment Overview Arcutis (NASDAQ:ARQT) IPO’d back in January 2020, raising ~$160m via the issuance of 9.375m shares priced at $17 per share. At the time, the company described itself as follows: a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or…